HIV Diagnostics Market Size By Test Type, By End-use, Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022

Description

List of Tables

The HIV diagnostics market is set to witness rapid growth through 2028 owing to rising HIV infections in under-developed and developed nations globally. In addition, rising adoption of home kits for diagnosis, along with increasing focus of government and private organizations on the development of effective diagnosis techniques, is anticipated to further drive the growth of the market over the forecast timeline.

According to the World Health Organization (WHO), in 2020, around 37.7 million people across the globe were living with HIV. Notably, nearly 40% of HIV infections are transmitted by people who are unaware that they have the virus. For people who have not been diagnosed, HIV testing is the first step towards maintaining a healthy life.

The Center for Disease Control and Prevention (CDC) suggests that everyone between the age of 13 and 64 should get tested for HIV at least once as part of their routine check-up. Moreover, people diagnosed with HIV should start treatment with antiretroviral therapy or ART. Not to mention, a large part of the fight against HIV globally has been raising awareness amongst people about the disease, including its diagnosis & testing and adoption of preventative drugs. To that effect, numerous non-governmental organizations are taking initiatives to spread awareness about HIV.

For instance, the Joint United Nations Programme on HIV/AIDS is a global unit that is leading the effort to wipe off the infection by 2030 internationally as part of its Sustainable Development Goals. For this purpose, the organization offers strategic direction, coordination, advocacy, and technical support to assist in connecting and catalyzing leadership from governments, communities, and private sector to provide life-saving HIV services. As a result, ongoing R&D activities in HIV diagnostics, like enhanced sensitivity for early or acute detection of the infection have created massive growth opportunities for the industry.

Overall, the HIV diagnostics market has been segregated in terms of test type, end-use and region. With reference to test type, the market has been classified into viral load test, antibody test, and CD4 tests. Among these, the antibody test segment held a market share of about 5% in 2021 and is poised to exhibit sturdy growth over 2022-2028. The growth of this segment is mainly due to the surging number of infections in underdeveloped and developing nations.

Based on end-use, the HIV diagnostics market has been segmented into hospitals & clinics, diagnostic laboratories, home settings, and others. The home settings segment is likely to depict a CAGR of more than 1.1% between 2022 and 2028 driven by the development of new in-home testing products.

From the regional point, the North America HIV diagnostics market exceeded a valuation of USD 60 million in 2021 and is set to observe moderate growth through the forecast period. Declining HIV cases are speculated to impede regional market growth.

Product Code: 491

Chapter 1 Methodology

1.1 Methodology
1.2 Market definitions
- 1.2.1 North America
- 1.2.2 Europe
- 1.2.3 Asia Pacific
- 1.2.4 Latin America
- 1.2.5 Middle East
- 1.2.6 Africa
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 HIV diagnostics industry 360 degree synopsis
- 2.1.1 Business trends
- 2.1.2 Test type trends
- 2.1.3 End-use trends
- 2.1.4 Regional trends

Chapter 3 HIV Diagnostics Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028 (USD Million)
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Favorable regulatory landscape in U
  - 3.3.1.2 Point of Care (P-o-C) HIV diagnostics development
  - 3.3.1.3 Increasing HIV prevalence in low and middle-income countries
  - 3.3.1.4 Increasing government initiatives for HIV awareness
- 3.3.2 Industry pitfalls and challenges
  - 3.3.2.1 Low degree of penetration in undeveloped regional markets
  - 3.3.2.2 Growing awareness regarding HIV transmission and testing
  - 3.3.2.3 Reduction of HIV cases in developed countries
3.4 Growth potential analysis
- 3.4.1 By test type
- 3.4.2 By end-use
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 Competitive landscape, 2021
- 3.8.1 Competitive matrix analysis, 2021
3.9 PESTEL analysis

Chapter 4 HIV Diagnostics Market, By Test Type

4.1 Key segment trends
4.2 Antibody test
- 4.2.1 Market size, by region, 2017 - 2028 (USD Million)
4.3 Viral load test
- 4.3.1 Market size, by region, 2017 - 2028 (USD Million)
4.4 CD4 test
- 4.4.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 5 HIV Diagnostics Market, By End-use

5.1 Key segment trends
5.2 Diagnostic laboratories
- 5.2.1 Market size, by region, 2017 - 2028 (USD Million)
5.3 Hospitals & clinics
- 5.3.1 Market size, by region, 2017 - 2028 (USD Million)
5.4 Home settings
- 5.4.1 Market size, by region, 2017 - 2028 (USD Million)
5.5 Others
- 5.5.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 6 HIV Diagnostics Market, By Region

6.1 Key regional trends
6.2 North America
- 6.2.1 Market size, by country 2017 - 2028 (USD Million)
- 6.2.2 Market size, by test type, 2017 - 2028 (USD Million)
- 6.2.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.2.4 U.S.
  - 6.2.4.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.2.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.2.5 Canada
  - 6.2.5.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.2.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
6.3 Europe
- 6.3.1 Market size, by country 2017 - 2028 (USD Million)
- 6.3.2 Market size, by test type, 2017 - 2028 (USD Million)
- 6.3.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.4 Russia
  - 6.3.4.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.3.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.5 France
  - 6.3.5.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.3.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.6 Spain
  - 6.3.6.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.3.6.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.7 Italy
  - 6.3.7.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.3.7.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.8 UK
  - 6.3.8.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.3.8.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.9 Germany
  - 6.3.9.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.3.9.2 Market size, by end-use, 2017 - 2028 (USD Million)
6.4 Asia Pacific
- 6.4.1 Market size, by country 2017 - 2028 (USD Million)
- 6.4.2 Market size, by test type, 2017 - 2028 (USD Million)
- 6.4.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.4.4 India
  - 6.4.4.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.4.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.4.5 China
  - 6.4.5.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.4.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
6.5 Latin America
- 6.5.1 Market size, by country 2017 - 2028 (USD Million)
- 6.5.2 Market size, by test type, 2017 - 2028 (USD Million)
- 6.5.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.5.4 Brazil
  - 6.5.4.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.5.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.5.5 Mexico
  - 6.5.5.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.5.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.5.6 Argentina
  - 6.5.6.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.5.6.2 Market size, by end-use, 2017 - 2028 (USD Million)
6.6 Middle East
- 6.6.1 Market size, by country 2017 - 2028 (USD Million)
- 6.6.2 Market size, by test type, 2017 - 2028 (USD Million)
- 6.6.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.6.4 Iran
  - 6.6.4.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.6.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.6.5 Saudi Arabia
  - 6.6.5.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.6.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.6.6 Yemen
  - 6.6.6.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.6.6.2 Market size, by end-use, 2017 - 2028 (USD Million)
6.7 Africa
- 6.7.1 Market size, by country 2017 - 2028 (USD Million)
- 6.7.2 Market size, by test type, 2017 - 2028 (USD Million)
- 6.7.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.7.4 South Africa
  - 6.7.4.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.7.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.7.5 Mozambique
  - 6.7.5.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.7.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.7.6 Nigeria
  - 6.7.6.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.7.6.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.7.7 United Republic of Tanzania
  - 6.7.7.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.7.7.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.7.8 Kenya
  - 6.7.8.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.7.8.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.7.9 Uganda
  - 6.7.9.1 Market size, by test type, 2017 - 2028 (USD Million)
  - 6.7.9.2 Market size, by end-use, 2017 - 2028 (USD Million)

Chapter 7 Company Profiles

7.1 Strategy dashboard, 2021
7.2 Abbott
- 7.2.1 Business overview
- 7.2.2 Financial data
- 7.2.3 Product landscape
- 7.2.4 Strategic outlook
- 7.2.5 SWOT analysis
7.3 OraSure Technologies.
- 7.3.1 Business overview
- 7.3.2 Financial data
- 7.3.3 Product landscape
- 7.3.4 Strategic outlook
- 7.3.5 SWOT analysis
7.4 BD
- 7.4.1 Business overview
- 7.4.2 Financial data
- 7.4.3 Product landscape
- 7.4.4 Strategic outlook
- 7.4.5 SWOT analysis
7.5 BIONEER CORPORATION
- 7.5.1 Business overview
- 7.5.2 Financial data
- 7.5.3 Product landscape
- 7.5.4 Strategic outlook
- 7.5.5 SWOT analysis
7.6 bioMérieux SA
- 7.6.1 Business overview
- 7.6.2 Financial data
- 7.6.3 Product landscape
- 7.6.4 Strategic outlook
- 7.6.5 SWOT analysis
7.7 ChemBio Diagnostics Inc.
- 7.7.1 Business overview
- 7.7.2 Financial data
- 7.7.3 Product landscape
- 7.7.4 Strategic outlook
- 7.7.5 SWOT analysis
7.8 Qiagen
- 7.8.1 Business overview
- 7.8.2 Financial data
- 7.8.3 Product landscape
- 7.8.4 Strategic outlook
- 7.8.5 SWOT analysis
7.9 Roche Diagnostics
- 7.9.1 Business overview
- 7.9.2 Financial data
- 7.9.3 Product landscape
- 7.9.4 Strategic outlook
- 7.9.5 SWOT analysis
7.10 Cepheid
- 7.10.1 Business overview
- 7.10.2 Financial data
- 7.10.3 Product landscape
- 7.10.4 Strategic outlook
- 7.10.5 SWOT analysis
7.11 Omega Diagnostics
- 7.11.1 Business overview
- 7.11.2 Financial data
- 7.11.3 Product landscape
- 7.11.4 Strategic outlook
- 7.11.5 SWOT analysis